PL438001A1 - Muteiny ludzkiego czynnika wzrostu fibroblastów 1 (FGF-1), ich dimery i zastosowania - Google Patents

Muteiny ludzkiego czynnika wzrostu fibroblastów 1 (FGF-1), ich dimery i zastosowania

Info

Publication number
PL438001A1
PL438001A1 PL438001A PL43800121A PL438001A1 PL 438001 A1 PL438001 A1 PL 438001A1 PL 438001 A PL438001 A PL 438001A PL 43800121 A PL43800121 A PL 43800121A PL 438001 A1 PL438001 A1 PL 438001A1
Authority
PL
Poland
Prior art keywords
muteins
fgf
dimers
applications
growth factor
Prior art date
Application number
PL438001A
Other languages
English (en)
Other versions
PL244541B1 (pl
Inventor
Jacek Józef OTLEWSKI
Małgorzata Urszula ZAKRZEWSKA
Daniel Rafał KROWARSCH
Aleksandra Czyrek
Michał Mieczysław JANISZEWSKI
Jerzy Szczepan Pieczykolan
Ewa DRZAZGA
Katarzyna BAZYDŁO-GUZENDA
Paweł BUDA
Maciej Wieczorek
Original Assignee
Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością
Uniwersytet Wrocławski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością, Uniwersytet Wrocławski filed Critical Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL438001A priority Critical patent/PL244541B1/pl
Priority to CA3219971A priority patent/CA3219971A1/en
Priority to US18/564,350 priority patent/US20250282841A1/en
Priority to JP2023573125A priority patent/JP2024520065A/ja
Priority to AU2022279881A priority patent/AU2022279881B9/en
Priority to MX2023013964A priority patent/MX2023013964A/es
Priority to CN202280038116.7A priority patent/CN117425669A/zh
Priority to KR1020237044856A priority patent/KR20240013800A/ko
Priority to BR112023024645A priority patent/BR112023024645A2/pt
Priority to KR1020237044867A priority patent/KR20240013801A/ko
Priority to JP2023573127A priority patent/JP2024520066A/ja
Priority to MX2023013963A priority patent/MX2023013963A/es
Priority to BR112023024658A priority patent/BR112023024658A2/pt
Priority to PCT/PL2022/050032 priority patent/WO2022250555A1/en
Priority to PCT/PL2022/050033 priority patent/WO2022250556A1/en
Priority to EP22743606.0A priority patent/EP4347630A1/en
Priority to AU2022282069A priority patent/AU2022282069A1/en
Priority to CN202280038168.4A priority patent/CN117730092A/zh
Priority to EP22743607.8A priority patent/EP4347631A1/en
Priority to CA3219965A priority patent/CA3219965A1/en
Publication of PL438001A1 publication Critical patent/PL438001A1/pl
Publication of PL244541B1 publication Critical patent/PL244541B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem niniejszego wynalazku są muteiny ludzkiego czynnika wzrostu fibroblastów 1 (FGF-1) o obniżonej mitogenności, dimery mutein ludzkiego FGF-1, a także takie muteiny ludzkiego FGF-1, i dimery takich mutein do zastosowania w obniżaniu poziomu glukozy we krwi, zwłaszcza do zastosowania w leczeniu cukrzycy.
PL438001A 2021-05-26 2021-05-26 Muteiny ludzkiego czynnika wzrostu fibroblastów 1 (FGF-1), ich dimery i zastosowania PL244541B1 (pl)

Priority Applications (20)

Application Number Priority Date Filing Date Title
PL438001A PL244541B1 (pl) 2021-05-26 2021-05-26 Muteiny ludzkiego czynnika wzrostu fibroblastów 1 (FGF-1), ich dimery i zastosowania
CA3219971A CA3219971A1 (en) 2021-05-26 2022-05-25 Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
US18/564,350 US20250282841A1 (en) 2021-05-26 2022-05-25 Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
JP2023573125A JP2024520065A (ja) 2021-05-26 2022-05-25 ヒト線維芽細胞増殖因子１（ｆｇｆ－１）ミューテイン、その二量体および使用
AU2022279881A AU2022279881B9 (en) 2021-05-26 2022-05-25 Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
MX2023013964A MX2023013964A (es) 2021-05-26 2022-05-25 Muteinas del factor de crecimiento de fibroblastos humanos 1 (fgf-1), sus dimeros y usos.
CN202280038116.7A CN117425669A (zh) 2021-05-26 2022-05-25 人成纤维细胞生长因子1(fgf-1)突变蛋白、其二聚体和用途
KR1020237044856A KR20240013800A (ko) 2021-05-26 2022-05-25 인간 섬유모세포 성장인자 1 (fgf-1) 뮤테인, 이의 이량체 및 용도
BR112023024645A BR112023024645A2 (pt) 2021-05-26 2022-05-25 Muteínas do fator de crescimento de fibroblastos humano 1 (fgf-1), dímeros e usos das mesmas
KR1020237044867A KR20240013801A (ko) 2021-05-26 2022-05-25 인간 섬유모세포 성장인자 1 (fgf-1) 뮤테인, 이의 이량체 및 용도
JP2023573127A JP2024520066A (ja) 2021-05-26 2022-05-25 ヒト線維芽細胞増殖因子１（ｆｇｆ－１）ミューテイン、その二量体および使用
MX2023013963A MX2023013963A (es) 2021-05-26 2022-05-25 Muteinas del factor de crecimiento de fibroblastos humanos 1 (fgf-1), sus dimeros y usos.
BR112023024658A BR112023024658A2 (pt) 2021-05-26 2022-05-25 Muteínas do fator de crescimento de fibroblastos humano 1 (fgf-1), dímeros e usos das mesmas
PCT/PL2022/050032 WO2022250555A1 (en) 2021-05-26 2022-05-25 Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
PCT/PL2022/050033 WO2022250556A1 (en) 2021-05-26 2022-05-25 Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
EP22743606.0A EP4347630A1 (en) 2021-05-26 2022-05-25 Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
AU2022282069A AU2022282069A1 (en) 2021-05-26 2022-05-25 Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
CN202280038168.4A CN117730092A (zh) 2021-05-26 2022-05-25 人成纤维细胞生长因子1(fgf-1)突变蛋白、其二聚体和用途
EP22743607.8A EP4347631A1 (en) 2021-05-26 2022-05-25 Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
CA3219965A CA3219965A1 (en) 2021-05-26 2022-05-25 Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438001A PL244541B1 (pl) 2021-05-26 2021-05-26 Muteiny ludzkiego czynnika wzrostu fibroblastów 1 (FGF-1), ich dimery i zastosowania

Publications (2)

Publication Number Publication Date
PL438001A1 true PL438001A1 (pl) 2022-11-28
PL244541B1 PL244541B1 (pl) 2024-02-05

Family

ID=82594666

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438001A PL244541B1 (pl) 2021-05-26 2021-05-26 Muteiny ludzkiego czynnika wzrostu fibroblastów 1 (FGF-1), ich dimery i zastosowania

Country Status (11)

Country Link
US (1) US20250282841A1 (pl)
EP (2) EP4347630A1 (pl)
JP (2) JP2024520066A (pl)
KR (2) KR20240013800A (pl)
CN (2) CN117425669A (pl)
AU (2) AU2022279881B9 (pl)
BR (2) BR112023024658A2 (pl)
CA (2) CA3219965A1 (pl)
MX (2) MX2023013964A (pl)
PL (1) PL244541B1 (pl)
WO (2) WO2022250556A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025038759A1 (en) * 2023-08-14 2025-02-20 The Board Of Trustees Of The University Of Arkansas Engineered fgf1/fgf2 fused heterodimer compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
WO2014084027A1 (ja) * 2012-11-28 2014-06-05 独立行政法人放射線医学総合研究所 細胞膜透過性の線維芽細胞増殖因子の医療用途
WO2015061361A1 (en) * 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
AU2016252423A1 (en) * 2015-04-20 2017-11-23 Florida State University Research Foundation, Incorporated Fibroblast growth factor (FGF) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
JP2018535964A (ja) * 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
EP3491011A1 (en) * 2016-08-01 2019-06-05 Salk Institute for Biological Studies Fibroblast growth factor (fgf) 1 proteins with glucose lowering ability and reduced mitogenicity
WO2018112200A1 (en) * 2016-12-15 2018-06-21 Salk Institute For Biological Studies Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemia
US11542309B2 (en) * 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose

Also Published As

Publication number Publication date
WO2022250555A1 (en) 2022-12-01
PL244541B1 (pl) 2024-02-05
JP2024520066A (ja) 2024-05-21
CN117425669A (zh) 2024-01-19
AU2022282069A1 (en) 2023-12-21
AU2022279881B9 (en) 2026-03-05
AU2022279881A1 (en) 2023-12-21
EP4347630A1 (en) 2024-04-10
CA3219971A1 (en) 2022-12-01
WO2022250556A1 (en) 2022-12-01
MX2023013963A (es) 2024-03-08
WO2022250556A4 (en) 2023-02-16
KR20240013801A (ko) 2024-01-30
EP4347631A1 (en) 2024-04-10
US20250282841A1 (en) 2025-09-11
CN117730092A (zh) 2024-03-19
AU2022279881A9 (en) 2026-03-05
BR112023024645A2 (pt) 2024-02-20
CA3219965A1 (en) 2022-12-01
KR20240013800A (ko) 2024-01-30
JP2024520065A (ja) 2024-05-21
MX2023013964A (es) 2024-03-08
BR112023024658A2 (pt) 2024-02-20
WO2022250555A4 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
Kamiya et al. Sternal microcirculation after skeletonized versus pedicled harvesting of the internal thoracic artery: a randomized study
IS8909A (is) Rauðkornavaki til örvunar á innanþekju forverafrumum.
DE60115498D1 (de) Chirurgische vorrichtungen
Balcin et al. A comparative study of two methods of surgical treatment for painful neuroma
Saint et al. Risk reduction in the intensive care unit
Tejiram et al. Innovations in infection prevention and treatment
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
BR112023024645A2 (pt) Muteínas do fator de crescimento de fibroblastos humano 1 (fgf-1), dímeros e usos das mesmas
Ibrahim Metalloproteins and metalloproteomics in health and disease
ZA202310748B (en) Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin
AU2022279881B2 (en) Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
MX375350B (es) Medicamento para el tratamiento de infecciones de pie diabetico
Kung et al. An individualized approach to severe elbow burn contractures
MX2024011514A (es) Preparacion de un inmunoconjugado de il2.
PL445849A1 (pl) Muteiny ludzkiego czynnika wzrostu fibroblastów 1 (FGF-1), ich dimery i zastosowania
BRPI0517406A (pt) método de tratamento, controle ou redução do risco de uma infecção bacteriana e um estado de insuficiência cardìaca em um ser humano; método para controle do aumento dos nìveis plasmáticos de digoxina em estado constante em um ser humano; método de tratamento, controle ou redução do risco de uma infecção bacteriana com tigeciclina em um paciente; uso de tigeciclina em combinação com digoxina; e produto compreendendo tigeciclina e digoxina como uma preparação combinada
Sharma et al. Burn injuries in clinical practice: Principles and management for general physicians
Karamürsel et al. Dorsal visor flap in fingertip reconstruction
Moore et al. The use of debridement in the healing of diabetic foot ulcers.
Bandyk Lower-limb wound evaluation and care in the vascular surgery patient
BR212022011734U2 (pt) Dispositivo para tratamento de feridas e meios de utilização
Krivoschekov et al. Acute varicotrombomphlebitis: treatment with oral subtilisins
DE10345401A1 (de) Verwendung von alpha-Linolensäure und alpha-linolensäurehaltigen Pflanzenölen
Balkanay et al. Does locally administered gentamicin affect the incidence of sternal wound infections after coronary artery bypass graft surgery
Bhutani et al. Hyperbaric oxygen therapy in non-healing wounds